Crohn's Disease Classification and Management

Introduction to Crohn's Disease Classification

The Montreal Classification system is used to classify Crohn's disease, categorizing patients by age at diagnosis, disease location, and disease behavior, guiding treatment decisions and prognostic assessment, as endorsed by major gastroenterology societies 1, 2, 3.

The American Gastroenterological Association recommends using the Montreal Classification system, which includes age at diagnosis (A1: ≤16 years, A2: 17-40 years, A3: >40 years) 1, 2.
Disease location is classified as L1: Ileal, L2: Colonic, L3: Ileocolonic, and L4: Upper gastrointestinal disease, with L4 able to be added to L1-L3 when concomitant upper GI disease exists 1, 2, 4.
Disease behavior is classified as B1: Non-stricturing, non-penetrating, B2: Stricturing, B3: Penetrating, with a "p" modifier for perianal disease 1, 2, 4, 5.

Younger age at diagnosis (A1, A2) correlates with more extensive disease, greater need for immunosuppression, and more complex disease behavior, according to the International Organization for the Study of Inflammatory Bowel Disease 2, 6.
The Crohn's Disease Activity Index (CDAI) is used to assess disease activity, with scores ranging from remission (<150) to severe (>450), although it has limitations in correlating with endoscopic severity and biomarkers, as noted by the American College of Gastroenterology 2, 5, 7.

The Harvey-Bradshaw Index (HBI) is a simpler alternative to CDAI, with scores ranging from remission (≤4) to active disease, but also has limitations in symptom-weighting and correlation with objective inflammation, as reported by the European Crohn's and Colitis Organisation 2, 3, 5.
Endoscopic scoring systems, such as CDEIS and SES-CD, provide an objective assessment of mucosal inflammation, which correlates better with long-term outcomes than symptom scores, according to the World Gastroenterology Organisation 3.

The International Organization for the Study of Inflammatory Bowel Disease defines severe disease based on high risk for adverse complications, including structural factors (large/deep mucosal lesions, fistula, strictures, prior intestinal resections), inflammatory burden (elevated CRP, low albumin, anemia), and symptomatic criteria (loose stools, abdominal pain, anorectal symptoms), as outlined by the American Gastroenterological Association 4, 5, 7.

The European Crohn's and Colitis Organisation notes that inflammation frequently persists without gastrointestinal symptoms, potentially leading to progressive bowel damage, highlighting the need for objective monitoring with biomarkers and endoscopy, even in asymptomatic patients 8.
Histologic inflammation may be more extensive than macroscopic extent, as shown in pediatric studies, emphasizing the importance of histologic evaluation, as recommended by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition 3.